Avelumab in Third-Line Gastric Cancer

Update Il y a 4 ans
Reference: EUCTR2015-003301-42

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective is to demonstrate superiority with regard to overall survival (OS) of avelumab plus best supportive care (BSC) versus physician’s choice (chosen from a pre-specified list of therapeutic options) plus BSC.


Inclusion criteria

  • Unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma